BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, April 20, 2026
Home » Authors » Brady Huggett

Articles by Brady Huggett

Ribapharm Enters Record Books With Long-Awaited $260M IPO

April 15, 2002
By Brady Huggett
It’s been a long time coming, but well worth the wait. Ribapharm Inc., having filed for its initial public offering in June 2000, got the deal done Friday, pricing 26 million shares at $10 apiece, raising $260 million and entering biotechnology’s IPO record book. (BioWorld Today)
Read More

Isis Presents Interim ISIS 2503 Phase II Pancreatic Cancer Data

April 11, 2002
By Brady Huggett

Isis Presents Interim ISIS 2503 Phase II Pancreatic Cancer Data

April 11, 2002
By Brady Huggett

ImClone Presents Preclinical Data Of Erbitux In Combination Study

April 10, 2002
By Brady Huggett

ImClone Presents Preclinical Data Of Erbitux In Combination Study

April 10, 2002
By Brady Huggett

Ceres Applying Genomics To Crops In Potential $137M Deal

April 4, 2002
By Brady Huggett
Money doesn’t grow on trees, but there’s certainly money to be made by growing better crops. Ceres Inc. signed on to apply its genomics technologies in the quest for improved agricultural harvests with Monsanto Co. in a collaboration that could bring Ceres a bounty of $137 million. (BioWorld Today)
Read More

Ceres Applying Genomics To Crops In Potential $137M Deal

April 4, 2002
By Brady Huggett
Money doesn’t grow on trees, but there’s certainly money to be made by growing better crops. Ceres Inc. signed on to apply its genomics technologies in the quest for improved agricultural harvests with Monsanto Co. in a collaboration that could bring Ceres a bounty of $137 million. (BioWorld Today)
Read More

Kalypsys Raises $43M In First Round, Plans Platform Growth

April 3, 2002
By Brady Huggett
Kalypsys Inc. raised $43 million in its first round of financing and will now look to grow the technology that gave it its start. (BioWorld Today)
Read More

Kalypsys Raises $43M In First Round, Plans Platform Growth

April 3, 2002
By Brady Huggett
Kalypsys Inc. raised $43 million in its first round of financing and will now look to grow the technology that gave it its start. (BioWorld Today)
Read More

Biopure’s Stock Rises on Blood Substitute Phase III Study Data

March 21, 2002
By Brady Huggett
Previous 1 2 … 64 65 66 67 68 69 70 71 72 73 74 75 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 20, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • Novel caspase-2 inhibitor shows in vivo neuroprotective effects

    BioWorld Science
    Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing